Thonzonium

Summary

Thonzonium (CHEMBL1201322) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 511.8 Da · C32H55N4O+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201322
Name	Thonzonium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5456
Molecular formula	C32H55N4O+
Molecular weight	511.8
InChIKey	IOYZYMQFUSNATM-UHFFFAOYSA-N

SMILES: CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(C=C1)OC)C2=NC=CC=N2

IUPAC name: hexadecyl-[2-[(4-methoxyphenyl)methyl-pyrimidin-2-ylamino]ethyl]-dimethylazanium

Also known as: Thonzonium cation, Thonzonium ion, Tonzonium, SID11112412, Thonzonium, TONZONIUM [BROMIDE], thonzonium bromide, THONZONIUM

Parent form; salt/anhydrous children: CHEMBL1200883

Patent coverage: 24 distinct patent families (34 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Ubiquitin carboxyl-terminal hydrolase 2, Nuclear receptor ROR-gamma, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Ferritin light chain, Thyrotropin receptor, Cytochrome P450 2D6, Cytochrome P450 1A2, Cytochrome P450 2C9.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.15	Potency	7080	nM	CHEMBL_ACT_3625381
USP2	5	Potency	10000	nM	CHEMBL_ACT_4743511

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).